Disease Areas
Equillium's novel immunomodulatory assets target immuno-inflammatory pathways.
Itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM
signaling pathway which plays a central role in the modulation of effector T
cells, is currently in a Phase 3 study for patients with acute
graft-versus-host disease (aGVHD) and is in a Phase 1b study for patients with
lupus/lupus nephritis.
EQ101, a first-in-class tri-specific cytokine inhibitor that selectively
targets IL-2, IL-9, and IL-15, is Phase 2 ready and expected to begin
enrolling patients in an alopecia areata study in the second half of 2022.
EQ102, a bi-specific cytokine inhibitor that selectively targets IL-15 and
IL-21, is ready for clinical development and expected to begin enrolling
patients in a Phase 1 study to include patients with celiac disease in the
second half of 2022.
Graft-Versus-Host Disease
Facebook
Hematopoietic stem cell transplant (HSCT) provides a potentially curative option for some types of cancer,
but it comes with the risk of GVHD. GVHD occurs when the transplanted immune system attacks the recipient’s
body and is the leading cause of non-cancer death in stem cell transplant recipients.
Learn About Graft-Versus-Host Desease
Lupus Nephritis
Facebook
Lupus nephritis is among the most serious complications of systemic lupus erythematosus (SLE), occurring in
30 – 60% of individuals with SLE. In lupus nephritis, the body’s own immune system attacks the kidneys,
causing inflammation and significantly reducing kidney function over time.
Learn About Lupus Nephritis